Open AccessEpidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study
Author(s) -
Łukasz Obołończyk,
Małgorzata Siekierska-Hellmann,
Piotr Wiśniewski,
Anna Lewczuk,
Monika Berendt-Obołończyk,
Anna Lakomy,
Z Michalska,
D Radowska,
Grażyna Moszkowska,
Agnieszka BianekBodzak,
Krzysztof Sworczak
Publication year - 2017
Publication title -
postępy higieny i medycyny doświadczalnej
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.275
H-Index - 34
eISSN - 1732-2693
pISSN - 0032-5449
DOI - 10.5604/01.3001.0010.4782
Subject(s) - medicine , euthyroid , thyroid , thyroiditis , ribavirin , autoantibody , anti thyroid autoantibodies , immunology , alpha interferon , autoimmune thyroiditis , hepatitis c virus , gastroenterology , interferon , virus , antibody
Hepatitis C virus (HCV) infection is a worldwide problem and hepatitis, which is its natural unfavourable course, is still a challenge for hepatologist. At present, standards of treatment are changing from combined therapy with interferon alpha (IFN-α) and ribavirin to new antiviral drugs. The current classification divides interferon induced thyroid diseases (IITD) into two groups: autoimmune (Hashimoto disease, Graves disease, positive antithyroid autoantibodies in euthyroid patients) and non-autoimmune (destructive thyroiditis, non-autoimmune hypothyroidism). A common complication of cytokine therapy is the induction of antithyroid autoantibodies de novo without thyroid dysfunction. During therapeutic regimens combined with ribavirin, destructive thyroiditis with typical biphasic course is more common than in IFN-α monotherapy. Clinically, overt pathologies often have discrete symptoms, which cause diagnostic and therapeutic dilemmas.